http://orcid.org/0000-0001-7794-7495
References
- GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269–285.
- Pirttisalo AL, Soilu-Hänninen M, Sipilä J. Multiple sclerosis epidemiology in Finland: regional differences and high incidence. Acta Neurol Scand. 2019;139(4):353–359.
- Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–911.
- Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
- Brundin L, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Sweden. Mult Scler. 2017;23(2_suppl):179–191.
- Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol. 2012;19(1):e11–25.
- Karampampa K, Gustavsson A, van Munster ET, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013;16(7):939–950.
- Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur J Neurol. 2005;12(s1):63–67.
- Kobelt G, Thompson A, Berg J, et al. MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136.
- Patti F, Amato MP, Trojano M, et al. Multiple sclerosis in Italy: cost-of-illness study. Neurol Sci. 2011;32(5):787–794.
- Gyllensten H, Kavaliunas A, Murley C, et al. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Mult Scler J Exp Transl Clin. 2019;5(2):2055217319858383.
- Ruutiainen J, Viita AM, Hahl J, et al. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. J Med Econ. 2016;19(1):21–33.
- Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(5):962–973.
- Krupp L, LaRocca N, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–1123.
- Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ. 2006;7(S02):5–13.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452.
- Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler. 2013;19(2):188–198.
- Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple Sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(1):133–146.
- Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–187.
- Rosti-Otajärvi E, Hämäläinen P, Wiksten A, et al. Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients. Brain Behav. 2017;7(7):e00743.
- Rosti-Otajärvi E, Hämäläinen P, Wiksten A, et al. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29. Brain Behav. 2017;7(7):e00725.
- Brochet B, Ruet A. Cognitive impairment in multiple sclerosis with regards to disease duration and clinical phenotypes. Front Neurol. 2019;20(10):261.
- Højsgaard Chow H, Schreiber K, Magyari M, et al. Progressive multiple sclerosis, cognitive function, and quality of life. Brain Behav. 2018;8(2):e00875.
- Heesen C, Schulz KH, Fiehler J, et al. Correlates of cognitive dysfunction in multiple sclerosis. Brain Behav Immun. 2010;24(7):1148–1155.
- Kavaliunas A, Manouchehrinia A, Danylaite Karrenbauer V, et al. Income in multiple sclerosis patients with different disease phenotypes. PLoS One. 2017;12(1):e0169460.
- Katz Sand I, Krieger S, Farrell C, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20(12):1654–1657.